Sight Sciences reports new data supporting long-term efficacy of OMNI Surgical System

Sight Sciences has released results from 3 published manuscripts analyzing prospective study data and retrospective registry data that the company claims “further demonstrate the value of an interventional mindset in treating glaucoma.”

One of the studies was a 24-month prospective study of 18 eyes with medication washout at baseline, 12 months, and 24 months of standalone OMNI use. Results showed that the mean baseline IOP of 26.1 mmHg was reduced an average of 9.7 mmHg at 12 months (p < .001) and 10.6 mmHg at 24 months (p < .001). Additionally, mean medications were reduced from 1.8 to 0.9 at 12 months (p < .001) and 0.5 at 24 months (p < .001). Of the patients, two-thirds were medication-free at month 24.

A retrospective, observational study observed nearly 13,000 African American eyes, of which 12,057 had only cataract surgery, 491 had iStent inject, 189 had Hydrus Microstent, and 91 had OMNI. Results showed that IOP reductions were higher in MIGS plus cataract surgery cohorts than cataract surgery alone, and that patients with a ≥20% reduction in IOP from baseline were greatest for OMNI, followed by Hydrus Microstent and iStent inject.

Finally, in a subgroup analysis of 220 eyes that had undergone a standalone OMNI procedure in primary open-angle glaucoma, IOP was significantly reduced for up to 3 years regardless of lens status or disease severity.

Paul Badawi, Founder and CEO of Sight Sciences and Leon Herndon, MD, Duke University Eye Center, Durham, NC, commented on the data.

“These results demonstrate that when surgeons are given the right solutions, they are able to reduce a patient’s intraocular eye pressure (IOP) and reliance on medication and maintain those reductions over an extended period of time, 24 months or 36 months,” said Badawi.

“OMNI continues to deliver results for patients, whether it be patients undergoing cataract surgery, those that have already had cataract surgery and are now pseudophakic, or groups at historically higher risk for glaucoma, as demonstrated by our study. It is important to have effective tools such as OMNI that are used especially for mild and moderate patients and can be utilized in conjunction with a cataract surgery or as a standalone procedure. That is especially true with African American patients, a cohort of patients that are often diagnosed at a later stage of disease,” added Herndon.

The OMNI Surgical System and OMNIEdge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

References:

1. New peer-reviewed publications highlight effectiveness of OMNI® Surgical System with TruSync™ Technology in reducing IOP and medication usage in cataract combination procedures, standalone procedures, and in African Americans. Published November 11, 2025. Accessed November 11, 2025. https://investors.sightsciences.com/news-releases/news-release-details/new-peer-reviewed-publications-highlight-effectiveness-omnir